Standout Papers

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, ... 2008 2026 2014 2020 509
  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 (2008)
    Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research

Citation Impact

1 by Nobel laureates 3 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

Renal cell carcinoma
2024 Standout
Photoinduced electron transfer (PeT) based fluorescent probes for cellular imaging and disease therapy
2023 Standout
6 intermediate papers

Works of Steve Bender being referenced

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity
2010
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
2008 Standout

Author Peers

Author Molecular Biology Oncology PRM Last Decade Papers Cites
Steve Bender 397 256 263 9 643
Elizabeth Greenhalgh 17 7 8 36 325
Nidhi Mishra 176 22 34 18 953
Deeb Taher 32 218 62 717
Lalitha Krishnan 292 101 122 47 971
Mi Sun Choe 185 128 207 22 642

All Works

Loading papers...

Rankless by CCL
2026